Isavuconazole (ISVZ) was developed as an alternative to voriconazole for invasive aspergillosis. Its pharmacological advantage regarding pharmacokinetics is:

• A Isavuconazole inhibits ergosterol synthesis without any CYP450 enzyme interaction, eliminating all drug-drug interactions
• B Isavuconazole does not require therapeutic drug monitoring because of its extremely short half-life of 4 hours
• C Isavuconazole targets beta-1,3-glucan synthase rather than CYP51 (lanosterol demethylase), providing a novel antifungal mechanism
• D Isavuconazole (prodrug isavuconazonium sulphate) has linear, predictable pharmacokinetics with no significant CYP2C19 polymorphism effect, avoiding the highly variable plasma levels seen with voriconazole in CYP2C19 poor vs. extensive metabolisers ✓

Explanation

Voriconazole's major clinical limitation is its non-linear, highly unpredictable pharmacokinetics, largely due to saturable CYP2C19-mediated metabolism. CYP2C19 poor metabolisers (more common in Asian populations, ~15-20%) have 3-4 fold higher voriconazole AUC than extensive metabolisers at the same dose, requiring therapeutic drug monitoring (TDM). Isavuconazonium sulphate is a water-soluble prodrug cleaved by plasma esterases to the active isavuconazole, which has linear pharmacokinetics and is primarily metabolised by CYP3A4 and CYP3A5 without significant CYP2C19 involvement, reducing pharmacogenomic variability. However, TDM is still recommended in critically ill patients. Isavuconazole still targets CYP51; echinocandins target glucan synthase.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.